II. Indications
- See ACE Inhibitor
III. Mechanism
- See ACE Inhibitor
- Non-sulfhydryl Angiotensin Converting Enzyme (ACE) inhibitor
- Moexipril is a prodrug, converted to its active form Moexiprilat via hydrolysis
IV. Dosing
- Adequate 24 hour Blood Pressure control may require twice daily dosing
- Take one hour before meals
-
Hypertension
- Start 7.5 mg orally daily
- Start 3.75 mg orally daily in renal dysfunction
- Target 7.5 to 30 mg orally daily or divided twice daily
- Maximum 30 mg/day (15 mg/day in renal dysfunction)
- Start 7.5 mg orally daily
V. Supplied
- Available as generic scored tablets (7.5, 15 mg)
VI. Metabolism
- Primarily hepatic metabolism
VII. Adverse Effects
- See ACE Inhibitor
VIII. Safety
- See ACE Inhibitor
- Pregnancy Category X
- Avoid in Lactation
IX. Resources
X. References
- (2016) Presc Lett, Resource #321151, ACE Inhibitor Antihypertensive Dose Comparison
- (2020) Med Lett Drugs Ther 62(1598): 73-80
- Olson (2020) Clinical Pharmacology, Medmaster Miami, p. 68-9
- Hamilton (2020) Tarascon Pocket Pharmacopoeia
Images: Related links to external sites (from Bing)
Related Studies
moexipril (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
MOEXIPRIL HCL 15 MG TABLET | Generic | $0.75 each |
MOEXIPRIL HCL 7.5 MG TABLET | Generic | $0.97 each |
Ontology: moexipril (C0066685)
Definition (NCI) | A non-sulfhydryl angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. As a prodrug, moexipril is hydrolyzed into its active form moexiprilat, which competitively inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This prevents the actions of the potent vasoconstrictor angiotensin II and leads to vasodilation. It also prevents angiotensin II-induced aldosterone secretion by the adrenal cortex, thereby promoting diuresis and natriuresis. |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C058302 |
SnomedCT | 108566003, 373442003 |
English | 2-((1-ethoxycarbony)-3-phenylpropylamino-1-oxopropyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, moexipril, MOEXIPRIL, moexipril [Chemical/Ingredient], Moexipril, Moexipril (product), Moexipril (substance) |
Spanish | moexipril (producto), moexipril (sustancia), moexiprilo, moexipril |
Ontology: Univasc (C0724125)
Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
MSH | C058302 |
English | univasc, Perdix, Moex, Schwarz brand of moexipril hydrochloride, Univasc |